AI was one of the biggest stories at the American Heart Association’s Scientific Sessions 2023 conference in Philadelphia. Researchers presented new data about heart attack care, voice recognition algorithms, digital stethoscopes and more. 

One key difference between this new risk calculator and previous methods is that it does not consider a patient's race or ethnicity. It does, however, consider such factors as where the patient lives, their education and their income level. 

Novo Nordisk shared initial results from the SELECT trial back in August, but now the full analysis—which includes data from more than 17,000 patients—has been published in The New England Journal of Medicine. 

He has agreed to pay an administrative fee of $1,100 within the next three months.

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.

The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all? 

Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.

“Marijuana use isn’t without its health concerns, and our study provides more data linking its use to cardiovascular conditions," one researcher said. 

The study focused on patients 65 years old and older who underwent treatment in one of 21 high-income countries.